Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Tamminga

Showing results (31-40 of 213) with videos related to

Pageof 22
Sort By:
Archives of General Psychiatry|March 1, 1995
Why neuroleptic withdrawal in schizophrenia?W T Carpenter, C A Tamminga
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 1, 1995
Recent developments in the neuropharmacology of schizophreniaA C Lahti, C A Tamminga
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 3, 1999
Effect of amphetamine, alpha-methyl-p-tyrosine (alpha-MPT) and antipsychotic agents on dopamine D2-type receptor occupancy in ratsR A Lahti, C A Tamminga
Biological Psychiatry|July 8, 1999
Schizophrenia research series: from molecule to public policyC A Tamminga, J A Lieberman
Molecular Psychiatry|September 2, 2004
Phenotype of schizophrenia: a review and formulationC A Tamminga, H H Holcomb
The American Journal of Psychiatry|May 1, 1995
Images in neuroscience. The hippocampus in epilepsyR S Sloviter, C A Tamminga
The Journal of Nervous and Mental Disease|December 1, 1982
The DSM-III diagnosis of schizophrenic-like illness and the clinical pharmacology of psychosisC A Tamminga, W T Carpenter
Expert Opinion on Investigational Drugs|July 2, 2005
Olanzapine (Zyprexa):characteristics of a new antipsychoticC A Tamminga, J M Kane
Psychopharmacology|January 1, 1979
Treatment of Schizophrenia with ergot derivativesC A Tamminga, M H Schaffer
The American Journal of Psychiatry|September 1, 1994
Human brain receptors, VIII. The distribution of ionotropic glutamate receptors in the human hippocampusX M Gao, C A Tamminga
Pageof 22

Showing results (31-40 of 213) with videos related to

Sort By:
Pageof 22
Archives of General Psychiatry|March 1, 1995
Why neuroleptic withdrawal in schizophrenia?W T Carpenter, C A Tamminga
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 1, 1995
Recent developments in the neuropharmacology of schizophreniaA C Lahti, C A Tamminga
Progress in Neuro-Psychopharmacology & Biological Psychiatry|December 3, 1999
Effect of amphetamine, alpha-methyl-p-tyrosine (alpha-MPT) and antipsychotic agents on dopamine D2-type receptor occupancy in ratsR A Lahti, C A Tamminga
Biological Psychiatry|July 8, 1999
Schizophrenia research series: from molecule to public policyC A Tamminga, J A Lieberman
Molecular Psychiatry|September 2, 2004
Phenotype of schizophrenia: a review and formulationC A Tamminga, H H Holcomb
The American Journal of Psychiatry|May 1, 1995
Images in neuroscience. The hippocampus in epilepsyR S Sloviter, C A Tamminga
The Journal of Nervous and Mental Disease|December 1, 1982
The DSM-III diagnosis of schizophrenic-like illness and the clinical pharmacology of psychosisC A Tamminga, W T Carpenter
Expert Opinion on Investigational Drugs|July 2, 2005
Olanzapine (Zyprexa):characteristics of a new antipsychoticC A Tamminga, J M Kane
Psychopharmacology|January 1, 1979
Treatment of Schizophrenia with ergot derivativesC A Tamminga, M H Schaffer
The American Journal of Psychiatry|September 1, 1994
Human brain receptors, VIII. The distribution of ionotropic glutamate receptors in the human hippocampusX M Gao, C A Tamminga
Pageof 22